[11] Ocular irritation, ocular pain, and visual impairment may occur during use of oxymetazoline ophthalmic solution
Here are some clinical trials to give you an idea of the range of dosages: For schizophrenia, a clinical trial using 2400 mg/day of NAC showed increased glutathione levels and decreased glutamate levels
Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates
This product is unique in that it offers a low ratio of reduced versus oxidized glutathione, which is a measure of cellular toxicity
These analgesic properties position DSIP as valuable research compound for developing non-opioid pain management strategies, understanding the relationship between sleep and pain processing, and investigating peptide-based approaches to chronic pain treatment
(This includes all complementary and traditional medicines)